Spark Therapeutics Inc. (NASDAQ:ONCE) CEO Jeffrey D. Marrazzo sold 5,000 shares of Spark Therapeutics stock in a transaction on Monday, October 17th. The stock was sold at an average price of $54.66, for a total transaction of $273,300.00. Following the completion of the transaction, the chief executive officer now directly owns 235,000 shares in the company, valued at $12,845,100. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
Spark Therapeutics Inc. (NASDAQ:ONCE) traded down 4.67% on Wednesday, reaching $51.39. 346,335 shares of the company were exchanged. Spark Therapeutics Inc. has a 52 week low of $21.20 and a 52 week high of $65.99. The stock’s market capitalization is $1.57 billion. The stock has a 50-day moving average price of $59.71 and a 200 day moving average price of $51.08.
Spark Therapeutics (NASDAQ:ONCE) last announced its quarterly earnings data on Wednesday, August 10th. The company reported ($1.04) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.97) by $0.07. Spark Therapeutics had a negative net margin of 366.76% and a negative return on equity of 26.96%. The firm earned $1.29 million during the quarter, compared to analysts’ expectations of $1.17 million. During the same period in the prior year, the company posted ($0.60) earnings per share. The company’s revenue for the quarter was up .0% on a year-over-year basis. Analysts forecast that Spark Therapeutics Inc. will post ($3.96) earnings per share for the current year.
Several large investors have recently made changes to their positions in ONCE. Royal Bank of Canada increased its stake in shares of Spark Therapeutics by 1,346.2% in the second quarter. Royal Bank of Canada now owns 11,280 shares of the company’s stock worth $577,000 after buying an additional 10,500 shares in the last quarter. Schwab Charles Investment Management Inc. increased its stake in shares of Spark Therapeutics by 50.6% in the second quarter. Schwab Charles Investment Management Inc. now owns 62,288 shares of the company’s stock worth $3,185,000 after buying an additional 20,920 shares in the last quarter. Legal & General Group Plc increased its stake in shares of Spark Therapeutics by 105.6% in the second quarter. Legal & General Group Plc now owns 2,714 shares of the company’s stock worth $138,000 after buying an additional 1,394 shares in the last quarter. Metropolitan Life Insurance Co. NY increased its stake in shares of Spark Therapeutics by 63.3% in the second quarter. Metropolitan Life Insurance Co. NY now owns 12,778 shares of the company’s stock worth $653,000 after buying an additional 4,955 shares in the last quarter. Finally, Iguana Healthcare Management LLC purchased a new stake in shares of Spark Therapeutics during the second quarter worth approximately $3,068,000. 78.84% of the stock is currently owned by institutional investors.
ONCE has been the topic of several analyst reports. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $94.00 price target (down from $100.00) on shares of Spark Therapeutics in a report on Thursday, June 23rd. SunTrust Banks Inc. lifted their price target on shares of Spark Therapeutics from $64.00 to $72.00 and gave the stock a “buy” rating in a report on Tuesday, June 21st. Zacks Investment Research raised shares of Spark Therapeutics from a “hold” rating to a “buy” rating and set a $66.00 price target on the stock in a report on Thursday, August 11th. Stifel Nicolaus assumed coverage on shares of Spark Therapeutics in a research note on Friday, September 2nd. They set a “buy” rating and a $73.00 price objective for the company. Finally, Jefferies Group reiterated a “hold” rating on shares of Spark Therapeutics in a research note on Friday, August 5th. Two investment analysts have rated the stock with a sell rating, five have given a hold rating and seven have given a buy rating to the company’s stock. Spark Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $59.50.
Spark Therapeutics Company Profile
Spark Therapeutics, Inc (Spark) is engaged in developing products in the field of gene therapy. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its SPK-RPE65 (voretigene neparvovec) targets genetic blinding conditions known as inherited retinal dystrophies (IRDs).
Receive News & Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.